Hovione says New Jersey site expansion will create 60 jobs

By Gareth Macdonald

- Last updated on GMT

Hovione says New Jersey site expansion will create 60 jobs

Related tags Pharmacology

Hovione has said the expansion of its API facility in East Windsor, New Jersey will create 60 jobs by 2019.

The Portuguese active pharmaceutical ingredient (API) manufacturer announced its intention to expand the facility in October​, explaining that the idea was to add spray drying capacity for potent drug actives.

Hovione has started work on the expansion according to spokeswoman Isabel Pina, who told us "today was the groundbreaking of the expansion.​"

The investment – financial terms of which were not provided - will add an additional 30,600 ft² (2,843 m²) and complement capacity at a pilot plant at the site.

It will create 60 new jobs over the next three years according to Hovione.

The new spray drying technology is due to be operational in 2017.

Expansion

The East Windsor facility has been the focus of a number of investments in recent months.

In March, Hovione partnered with Vertex Pharma to set up a continuous manufacturing line at the facility which will be used to make the latter firm’s cystic fibrosis dugs Kalydeco (ivacaftor) and Orkambi (ivacaftor/ lumacaftor).

Hovione’s most recent investment in spray drying capacity was at its facility in Loures, Portugal.

At the time Filipe Gaspar, VP of R&D at Hovione told us “Spray drying is becoming the leading platform to overcome the poor solubility of most modern oral drugs."

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars